Evaluating the Efficacy and Clinical Outcomes of Erdosteine in Chronic Obstructive Pulmonary Disease: A Clinical Perspective

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, and imposes a considerable burden on healthcare resources. On 2020 the COPD effected rate is lead an global mortality. An oral mucolytic medication called Erdosteine may help adults with thick mucus and expectoration difficulties manage chronic obstructive pulmonary disease (COPD). The study was designed a prospective single-center observational study in the department of pulmonology in the study period of 6 months on study site as Medicover Hospital (tertiary care hospital) Hi-tech city , Hyderabad. The size of the population are not more than 50 patients are enrolled in research study based on inclusion criteria. The result of the study was males were more affected in all categories, with the most significant difference observed in the group with two conditions. Cough mean significantly decreased by ~68.09%, showing substantial improvement post-treatment. A slight increase (~4.38%) in standard deviation suggests minor variation in response across patients. An outstanding finding from this study was the high adherence rate, with 88% of patients classified as having good adherence to Erdosteine therapy. High adherence is crucial for achieving desired therapeutic outcomes, especially in chronic diseases like COPD. The once-daily or twice-daily dosing regimen of Erdosteine, coupled with minimal adverse events, likely contributed to this adherence. The conclusion, Erdosteine was found to be a safe, effective, and well-tolerated therapeutic option in the symptomatic and inflammatory management of COPD. Further long-term studies are encouraged to explore its benefits in disease progression and exacerbation prevention.